ANRO News & Events

Alto Neuroscience announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 inhibitor, for the treatment of cognitive impairment associated with schizophrenia. Topline data from the Phase 2 proof-of-concept study are expected following completion of dosing and data analysis and are anticipated to guide future development decisions for ALTO-101.

Alto Neuroscience announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent protects an aspect of ALTO-207 - the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole.